{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T07:11:19Z","timestamp":1778310679194,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10072-026-08962-0","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:34:15Z","timestamp":1775435655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temporal evolution of antiparkinsonian drug prescription over 17\u00a0years: a real-world data analysis of Korean patients with Parkinson\u2019s disease"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1135-3392","authenticated-orcid":false,"given":"Bora","family":"Yoon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1916-7014","authenticated-orcid":false,"given":"Hwa Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"8962_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J et al (2017) Parkinson disease. Nat Rev Dis Primers 3:17013. https:\/\/doi.org\/10.1038\/nrdp.2017.13","journal-title":"Nat Rev Dis Primers"},{"key":"8962_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Chaudhuri KR, Jenner P (2017) Non-motor features of Parkinson disease. Nat Rev Neurosci 18:435\u2013450. https:\/\/doi.org\/10.1038\/nrn.2017.62","journal-title":"Nat Rev Neurosci"},{"key":"8962_CR3","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1007\/978-3-030-62059-2_213","volume-title":"NeuroPsychopharmacotherapy","author":"Y Mizuno","year":"2022","unstructured":"Mizuno Y (2022) Definition and Classification of Parkinsonian Drugs. In: Riederer P, Laux G, Nagatsu T, Le W, Riederer C (eds) NeuroPsychopharmacotherapy. Springer International Publishing, Cham, pp 2823\u20132852"},{"key":"8962_CR4","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K et al (2018) International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord 33:1248\u20131266. https:\/\/doi.org\/10.1002\/mds.27372","journal-title":"Mov Disord"},{"key":"8962_CR5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"J Jankovic","year":"2020","unstructured":"Jankovic J, Tan EK (2020) Parkinson\u2019s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 91:795\u2013808. https:\/\/doi.org\/10.1136\/jnnp-2019-322338","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8962_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","volume":"97","author":"T Pringsheim","year":"2021","unstructured":"Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ et al (2021) Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary. Neurology 97:942\u2013957. https:\/\/doi.org\/10.1212\/WNL.0000000000012868","journal-title":"Neurology"},{"key":"8962_CR7","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130\u20131139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83","journal-title":"Med Care"},{"key":"8962_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"key":"8962_CR9","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord 25:2649\u20132653. https:\/\/doi.org\/10.1002\/mds.23429","journal-title":"Mov Disord"},{"key":"8962_CR10","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin PC (2009) Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput 38:1228\u20131234. https:\/\/doi.org\/10.1080\/03610910902859574","journal-title":"Commun Stat Simul Comput"},{"key":"8962_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","volume":"6","author":"DS Nagin","year":"2010","unstructured":"Nagin DS, Odgers CL (2010) Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol 6:109\u2013138. https:\/\/doi.org\/10.1146\/annurev.clinpsy.121208.131413","journal-title":"Annu Rev Clin Psychol"},{"key":"8962_CR12","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1080\/03610926.2012.719986","volume":"43","author":"JD Nielsen","year":"2014","unstructured":"Nielsen JD, Rosenthal JS, Sun Y, Day DM, Bevc I, Duchesne T (2014) Group-based criminal trajectory analysis using cross-validation criteria. Commun Stat- Theory Methods 43:4337\u20134356","journal-title":"Commun Stat- Theory Methods"},{"key":"8962_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1951","volume":"358","author":"G Rogers","year":"2017","unstructured":"Rogers G, Davies D, Pink J, Cooper P (2017) Parkinson\u2019s disease: summary of updated NICE guidance. BMJ 358:j1951. https:\/\/doi.org\/10.1136\/bmj.j1951","journal-title":"BMJ"},{"key":"8962_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2020.100257","volume":"20","author":"M Suzuki","year":"2020","unstructured":"Suzuki M, Arai M, Hayashi A, Ogino M (2020) Prescription pattern of anti-Parkinson\u2019s disease drugs in Japan based on a nationwide medical claims database. eNeurologicalSci 20:100257. https:\/\/doi.org\/10.1016\/j.ensci.2020.100257","journal-title":"eNeurologicalSci"},{"key":"8962_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099021","volume":"9","author":"S Nakaoka","year":"2014","unstructured":"Nakaoka S, Ishizaki T, Urushihara H, Satoh T, Ikeda S, Yamamoto M et al (2014) Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010. PLoS ONE 9:e99021. https:\/\/doi.org\/10.1371\/journal.pone.0099021","journal-title":"PLoS ONE"},{"key":"8962_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.858139","volume":"13","author":"XQ Liu","year":"2022","unstructured":"Liu XQ, Wang XY, Shen HM, Pang WY, Zhong MK, Ma CL (2022) Real-world prescription patterns for patients with young-onset Parkinson\u2019s disease in China: a trend analysis from 2014 to 2019. Front Pharmacol 13:858139. https:\/\/doi.org\/10.3389\/fphar.2022.858139","journal-title":"Front Pharmacol"},{"key":"8962_CR17","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1007\/s00415-019-09360-7","volume":"266","author":"S Kasamo","year":"2019","unstructured":"Kasamo S, Takeuchi M, Ikuno M, Kawasaki Y, Tanaka S, Takahashi R et al (2019) Real-world pharmacological treatment patterns of patients with young-onset Parkinson\u2019s disease in Japan: a medical claims database analysis. J Neurol 266:1944\u20131952. https:\/\/doi.org\/10.1007\/s00415-019-09360-7","journal-title":"J Neurol"},{"key":"8962_CR18","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","volume":"384","author":"R Gray","year":"2014","unstructured":"Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C et al (2014) Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 384:1196\u20131205. https:\/\/doi.org\/10.1016\/S0140-6736(14)60683-8","journal-title":"Lancet"},{"key":"8962_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1056\/NEJMoa1809983","volume":"380","author":"CVM Verschuur","year":"2019","unstructured":"Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, van Hilten JJ et al (2019) Randomized delayed-start trial of Levodopa in Parkinson\u2019s disease. N Engl J Med 380:315\u2013324. https:\/\/doi.org\/10.1056\/NEJMoa1809983","journal-title":"N Engl J Med"},{"key":"8962_CR20","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A et al (2004) Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med 351:2498\u20132508. https:\/\/doi.org\/10.1056\/NEJMoa033447","journal-title":"N Engl J Med"},{"key":"8962_CR21","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1080\/14656566.2020.1805432","volume":"21","author":"S Cerri","year":"2020","unstructured":"Cerri S, Blandini F (2020) An update on the use of non-ergot dopamine agonists for the treatment of Parkinson\u2019s disease. Expert Opin Pharmacother 21:2279\u20132291. https:\/\/doi.org\/10.1080\/14656566.2020.1805432","journal-title":"Expert Opin Pharmacother"},{"key":"8962_CR22","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1056\/nejm200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484\u20131491. https:\/\/doi.org\/10.1056\/nejm200005183422004","journal-title":"N Engl J Med"},{"key":"8962_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.parkreldis.2019.06.001","volume":"65","author":"R Mehanna","year":"2019","unstructured":"Mehanna R, Jankovic J (2019) Young-onset Parkinson\u2019s disease: its unique features and their impact on quality of life. Parkinsonism Relat Disord 65:39\u201348. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.06.001","journal-title":"Parkinsonism Relat Disord"},{"key":"8962_CR24","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/s0140-6736(14)60962-4","volume":"384","author":"AE Lang","year":"2014","unstructured":"Lang AE, Marras C (2014) Initiating dopaminergic treatment in Parkinson\u2019s disease. Lancet 384:1164\u20131166. https:\/\/doi.org\/10.1016\/s0140-6736(14)60962-4","journal-title":"Lancet"},{"key":"8962_CR25","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s13311-020-00924-4","volume":"17","author":"MAC Sy","year":"2020","unstructured":"Sy MAC, Fernandez HH (2020) Pharmacological treatment of early motor manifestations of Parkinson disease (PD). Neurotherapeutics 17:1331\u20131338. https:\/\/doi.org\/10.1007\/s13311-020-00924-4","journal-title":"Neurotherapeutics"},{"key":"8962_CR26","doi-asserted-by":"publisher","unstructured":"Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, et al (2006) Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 13:1186\u2013202. https:\/\/doi.org\/10.1111\/j.1468-1331.2006.01548.x","DOI":"10.1111\/j.1468-1331.2006.01548.x"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-08962-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-08962-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-08962-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T06:31:37Z","timestamp":1778308297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-08962-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["8962"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-08962-0","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were conducted in accordance with the ethical standards of the Committee on Human Experimentation of our institution and the Declaration of Helsinki of 1975. This retrospective study was approved by the Institutional Review Board (IRB) of Konyang University Hospital (IRB No. KYUH 2023\u201306-027). As the KNHIS dataset is subject to strict confidentiality regulations mandated by the Korean government and the data provided to researchers have already been de-identified, the IRB waived the requirement for written informed consent for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None declared.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"401"}}